Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 51Lung Neoplasms 40Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 25Brain Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22Pancreatic Neoplasms 21Breast Neoplasms 20Glioma 19Squamous Cell Carcinoma of Head and Neck 18Glioblastoma 17Multiple Myeloma 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 13Carcinoma, Renal Cell 13Mouth Neoplasms 12Oropharyngeal Neoplasms 11Lymphoma, Mantle-Cell 11Carcinoma 11Triple Negative Breast Neoplasms 10Melanoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Laryngeal Neoplasms 10Ovarian Neoplasms 9Nasopharyngeal Carcinoma 8Lymphoma, Follicular 8Leukemia, Myeloid, Acute 8Hypopharyngeal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, B-Cell 7

Interventions

serabelisib 1sapanisertib 1Specimen Handling 1Restraint, Physical 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Carboplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Endometrioid × Magnetic Resonance Spectroscopy × Clear all
NCT05112601 2026-04-21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
81 enrolled
Gynecologic

Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡